I had the honor of joining 40 executive delegates for a week to observe the Irish healthcare system. While spending in the Irish healthcare system is just 7.2% of GDP, the public hospitals are filled to the gills.
On the positive side, everyone in Ireland has access to the public healthcare system, and spending is just 7.2% of GDP. The poorest and those over age 70 typically pay nothing. Nursing ratios are high, and drugs are quite affordable and available.
What's not so good is that the public hospitals are filled to the gills: It's not unusual to see six patients sharing one hospital room. Patients have affordable out-of-pocket costs thanks to the mostly tax-funded system, but timely access can be a challenge. At the public hospital our group toured, the emergency department actually had visiting hours posted on the wall because patients were expected to be there a long time. Another odd detail was that the hospital, although only 10 years old, didn't have air conditioning, and the windows only opened a few inches.
There's a fervent debate over the co-location proposal right now, and the country's top hospital leaders discussed the idea with our delegation and what it means for Ireland. We also heard a nitty-gritty policy overview from the Minister of Health and Children, the Honorable Mary Harney.
On the study mission, I also learned the United States does not have a monopoly on perverse incentives. Ireland's hospitals are crowded, but there's not much incentive for them to change that. Clinicians-who are unionized-enjoy job security and a great deal of autonomy. New doctors graduate medical school with no debt and many go on to work for an average income of about $470,000. There's little quality measurement, but health authorities are beginning to address it, just as we are in the United States.
What Ireland-dubbed the Celtic Tiger in recent years-has going for it now is a young demographic and economic growth. The inevitable slowing of the economy and aging of the population hasn't hit the radar yet, but it's possible Ireland will be able to learn something from the United States by then.
Most Patients With HS Aren’t Aware of Approved Treatments
May 1st 2025Treating hidradenitis suppurativa is complex and often requires taking a number of medications, including antibiotics, hormone therapies and immunosuppressants. However, many of these treatments are used off-label, and at this time, only two biologic therapies—Humira (adalimumab) and Cosentyx (secukinumab)— are approved by the FDA for HS treatment.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen